De-risking Clinical Trials: The BIAL Phase I Trial in Foresight.
作者信息
Cohen Adam F, van Smeden Jeroen, Webb David J
机构信息
DDCD Consulting, Leiden, The Netherlands.
Leiden University Medical Center, Leiden, The Netherlands.
出版信息
Clin Pharmacol Ther. 2022 Feb;111(2):362-365. doi: 10.1002/cpt.2498. Epub 2021 Dec 28.
Abstract
摘要
相似文献
1
De-risking Clinical Trials: The BIAL Phase I Trial in Foresight.
Clin Pharmacol Ther. 2022 Feb;111(2):362-365. doi: 10.1002/cpt.2498. Epub 2021 Dec 28.
2
[Analysis of bialaphos and its active metabolite L-glufosinate in biological specimens by HPLC].
Chudoku Kenkyu. 2009 Jun;22(2):113-20.
3
[Effect of bird-induced anus-lifting surgery combined with oral Relinqing Granules on LUTS/CP with damp heat syndrome: Evaluation by infrared thermal imaging].
Zhonghua Nan Ke Xue. 2023 Feb;29(2):158-164.
4
Safety in FIH Trials: A Summary of the Symposium "Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost".
Ther Innov Regul Sci. 2017 May;51(3):276-284. doi: 10.1177/2168479017706404.
5
Using strategic foresight to assess conservation opportunity.
Conserv Biol. 2014 Dec;28(6):1474-83. doi: 10.1111/cobi.12404. Epub 2014 Nov 7.
6
De-risking clinical trial failure through mechanistic simulation.
Immunother Adv. 2022 Aug 23;2(1):ltac017. doi: 10.1093/immadv/ltac017. eCollection 2022.
7
Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity.
Front Oncol. 2023 Nov 14;13:1266286. doi: 10.3389/fonc.2023.1266286. eCollection 2023.
8
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045.
9
Episodic foresight and schizophrenia.
Br J Clin Psychol. 2016 Jun;55(2):107-22. doi: 10.1111/bjc.12092. Epub 2015 Jul 14.
10
Strategic Foresight in the Federal Government: A Survey of Methods, Resources and Institutional Arrangements.
World Futures Rev. 2018;25:1-25. doi: 10.1177/1946756718814908.
引用本文的文献
1
The estimation and translation uncertainties in applying NOAEL to clinical dose escalation.
Clin Transl Sci. 2024 Jun;17(6):e13831. doi: 10.1111/cts.13831.
2
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2.
Br J Clin Pharmacol. 2024 Jul;90(7):1586-1599. doi: 10.1111/bcp.15949. Epub 2023 Nov 22.
3
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs.
Transl Psychiatry. 2023 Mar 1;13(1):74. doi: 10.1038/s41398-023-02353-1.
4
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.
J Psychopharmacol. 2022 Dec;36(12):1299-1314. doi: 10.1177/02698811221124792. Epub 2022 Oct 14.
本文引用的文献
1
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
Clin Pharmacol Ther. 2022 Feb;111(2):391-403. doi: 10.1002/cpt.2290. Epub 2021 Jun 24.
2
Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies.
Br J Clin Pharmacol. 2021 Jul;87(7):2723-2731. doi: 10.1111/bcp.14615. Epub 2020 Nov 20.
3
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
Clin Pharmacol Ther. 2021 Jun;109(6):1395-1415. doi: 10.1002/cpt.2009. Epub 2020 Nov 3.
4
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
Br J Clin Pharmacol. 2018 Jul;84(7):1401-1409. doi: 10.1111/bcp.13550. Epub 2018 May 30.
5
Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects.
Br J Clin Pharmacol. 2018 Jul;84(7):1457-1466. doi: 10.1111/bcp.13529. Epub 2018 May 15.
6
On authorship in the BJCP.
Br J Clin Pharmacol. 2017 Oct;83(10):2127-2130. doi: 10.1111/bcp.13385.
7
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.
Science. 2017 Jun 9;356(6342):1084-1087. doi: 10.1126/science.aaf7497.
8
Establishing risk of human experimentation with drugs: lessons from TGN1412.
Lancet. 2006 Oct 14;368(9544):1387-91. doi: 10.1016/S0140-6736(06)69562-7.
Zotero 插件